VIDEO: Mel Spigelman, MD, discusses TB drug pipeline
BOSTON — Mel Spigelman, MD, president and CEO of TB Alliance, discusses the drug development pipeline for tuberculosis here at ASM Microbe 2016. He said that many of the new drugs and regimens developed over the past few years show promise against multidrug-resistant TB, but that novel treatments are still necessary.
“We still need a lot more work, and many more new compounds that will eventuate into much better therapeutics,” he said.
Disclosure: Spigelman reports no relevant financial disclosures.